help button home button Biophys. J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, L.
Right arrow Articles by Zagorski, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, L.
Right arrow Articles by Zagorski, M. G.
Biophysical Journal 86:1-2 (2004)
© 2004 The Biophysical Society

Sorting Out the Driving Forces for Parallel and Antiparallel Alignment in the Aß Peptide Fibril Structure

Liming Hou and Michael G. Zagorski

Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106-7078

Correspondence: Address reprint requests to Liming Hou, E-mail: lxh32{at}po.cwru.edu; or Michael G. Zagorski, E-mail: mxz12{at}po.cwru.edu.

Protein misfolding and aggregation are now well-recognized processes that often lead to amyloid fibril formation (amyloidosis). Because these events are coupled with many types of human disease, the field of protein amyloidosis is under intense investigation. In the amyloid fibrils, the proteins adopt cross ß-pleated sheet structures with distinct tinctorial and morphological properties, and typically consist of long, unbranched filaments that bind to diagnostic dyes such as Thioflavin-T and Congo Red (Temussi et al., 2003Go). There are currently 24 proteins that produce amyloid fibrils associated with human disease (Westermark et al., 2002Go), including the Aß of Alzheimer's disease, prion of transmissible spongiform encephalopathies, amylin of maturity-onset diabetes, transthyretin of familial amyloidosis, huntingtin of Huntington's disease, and {alpha}-synuclein of Parkinson's disease. Albeit these proteins have very different primary sequences, molecular sizes, and folded tertiary structures, they all produce amyloid fibrils. Amyloidosis may also be a general property for all proteins, since de novo designed peptides and other naturally occurring proteins not associated with human disease (such as myoglobin) (Fandrich et al., 2001Go) can be encouraged to aggregate as amyloid fibrils.

Despite the plethora of research, details about the molecular mechanisms of amyloidosis are still lacking. Most scientists agree that unraveling the chemical mechanisms is absolutely essential for the development of specific inhibitors to prevent amyloidosis in humans. The most obvious missing details are high-resolution structural data, particularly regarding the soluble ß-sheet aggregates and the amyloid fibril structures. Given that amyloid fibrils are not amenable to standard x-ray crystallography (i.e., they do not form crystals), lower-resolution analytical techniques such as x-ray fibril diffraction, negative stain electron microscopy, and atomic force microscopy have been employed. Although these methods have provided valuable data about the fibril morphology, including the discovery of "toxic" intermediates such as the "protofibrils" (Caughey and Lansbury, 2003Go), they cannot provide critical atomic level structural information, such as what amino acids are interacting during the aggregation processes and whether or not the fibrils adopt unique, folded structures. In this regard, the work presented by the Tycko and Meredith research groups in this issue makes an important contribution about the Aß fibril structure of Alzheimer's disease. These research groups have excellent track records with handling the Aß peptide and were the first to demonstrate that the peptide adopts the rare parallel ß-sheet organization in the amyloid fibrils.

The recent finding that solid-state NMR spectroscopy is applicable to amyloid fibril structure determination represents a timely and significant breakthrough (Tycko, 2003Go). For biomolecules, solid-state NMR has unique capabilities, in that it can be used with samples of limited solubility that often precipitate as noncrystalline solids. Solid-state NMR can provide accurate distances and torsion angles between site-specific 15N- and/or 13C-labeled atoms, and, under certain conditions, the NMR constraints can generate structural models on par with those obtained by solution NMR and x-ray. Solid-state NMR is likewise a rapidly growing field, and studies of uniformly or specifically labeled samples have provided important information about membrane-bound peptide channels and the active sites of other membrane proteins (Thompson, 2002Go), both of which are systems not amenable to solution NMR or x-ray.

The predominate forms of the Alzheimer's Aß peptide are the 40-residue Aß(1–40) and 42-residue Aß(1–42). The earliest solid-state NMR studies utilized peptide fragments composed of regions important for amyloidosis, such as the Aß(34–42) and Aß(16–22) peptides, in which both form the antiparallel ß-sheet as the major structural motif. However, solid-state NMR studies of the longer 35-residue Aß(10–35) and native Aß(1–40) peptides found different results that were consistent with in-register parallel ß-sheet structures. The overall conclusion was that accurate structural models must use constraints obtained from the longer, full-length Aß peptides, and that despite the common cross ß-pleated sheet motif, specific structural details can be sequence dependent. Nonetheless, the parallel versus antiparallel variation was a conundrum, since the shorter Aß peptides still form classic amyloid fibrils based on Congo Red and electron microscopy.

As described in this issue, Gordon et al. contemplated that peptide amphiphilicity may influence the parallel versus antiparallel orientation. Inspection of the Aß primary sequence reveals that the Aß(16–22) and Aß(34–42) peptides are nonamphiphilic, whereas the Aß(10–35) and Aß(1–40) are amphiphilic. Additionally, the Aß(1–40) peptide has surfactant properties and forms micelles. Amphiphilicity would stabilize the parallel ß-sheet orientation and nonamphiphilicity the antiparallel, possibly by way of hydrogen-bonding or electrostatic interactions between oppositely charged side chains or termini.

To test this hypothesis, the Aß(16–22) peptide was made amphiphilic by attaching a long hydrophobic chain to one end of the molecule (Scheme 1). This objective was fulfilled by acylation of the N-terminus with octanoic acid (CH3(CH2)6COOH), which increased the peptide's amphiphilicity as measured from its stability at the air-water interface, but did not reduce its ability to form amyloid fibrils. Based on electron microscopy and Congo Red, the modified octanoyl-Aß(16–22) forms amyloid fibrils that are indistinguishable from those of unmodified Aß(16–22). Without a doubt, the hypothesis was proven accurate by solid-state NMR with peptides containing 13C- and 15N-labels at strategic sites, where the octanoyl-Aß(16–22) formed parallel ß-sheets and the Aß(16–22) antiparallel ß-sheets. For consistency, the NMR methods employed were identical to those used previously by the same group for generating the Aß(1–40) peptide model (Petkova et al., 2002Go), which included a combination of low-precision (linewidths and chemical shifts) and high-precision (distances and torsion angles) constraints. The labeling and dilution strategy utilized four different peptide mixtures and exemplifies the experience these groups have in studying the Aß by solid-state NMR.
SCHEME

The work of Gordon et al. in this issue has several important implications; notably, that peptide amphiphilicity is a critical parameter for controlling the ß-sheet organization of amyloid fibrils. This provides a rationale for the proclivity toward parallel or antiparallel arrangements and, more importantly, that amyloid-forming proteins may each adopt unique fibril structures that are only visible by high-resolution techniques such as NMR. The unique fibril structures and the importance of amphiphilicity suggest that specific compounds could be targeted toward inhibiting amyloidosis of a single or select group of proteins, possibly by altering the brain microenvironment in a manner to prevent formation of the native parallel arrangement. Related approaches with modulating the peptide amphiphilicity has been used in the design of tertiary and supramolecular structures and may also be useful in the development of self-assembling, nanoscale materials.

In closing, the article by Gordon et al. in this issue clearly shows that high-resolution structure determination is urgently needed in the amyloid research area, and that solid-state NMR has emerged as an indispensable tool in this endeavor.

Submitted on October 21, 2003; accepted for publication October 27, 2003.


    REFERENCES
 TOP
 REFERENCES
 
Caughey, B., and P. T. Lansbury, Jr. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:267–298.[Medline]

Fandrich, M., M. A. Fletcher, and C. M. Dobson. 2001. Amyloid fibrils from muscle myoglobin. Nature. 410:165–166.[Medline]

Petkova, A. T., Y. Ishii, J. J. Balbach, O. N. Antzutkin, R. D. Leapman, F. Delaglio, and R. Tycko. 2002. A structural model for Alzheimer's {beta}-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA. 99:16742–16747.[Abstract/Free Full Text]

Temussi, P. A., L. Masino, and A. Pastore. 2003. From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J. 22:355–361.[Medline]

Thompson, L. K. 2002. Solid-state NMR studies of the structure and mechanisms of proteins. Curr. Opin. Struct. Biol. 12:661–669.[Medline]

Tycko, R. 2003. Insights into the amyloid folding problem from solid-state NMR. Biochemistry. 42:3151–3159.[Medline]

Westermark, P., M. D. Benson, J. N. Buxbaum, A. S. Cohen, B. Frangione, S. Ikeda, C. L. Masters, G. Merlini, M. J. Saraiva, and J. D. Sipe. 2002. Amyloid fibril protein nomenclature. Amyloid. 9:197–200.[Medline]




This article has been cited by other articles:


Home page
Biophys. JHome page
D. J. V. A. dos Santos and L. A. Eriksson
Permeability of Psoralen Derivatives in Lipid Membranes
Biophys. J., October 1, 2006; 91(7): 2464 - 2474.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
P. Cioni, E. Bramanti, and G. B. Strambini
Effects of Sucrose on the Internal Dynamics of Azurin
Biophys. J., June 1, 2005; 88(6): 4213 - 4222.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
B. Hoff, E. Strandberg, A. S. Ulrich, D. P. Tieleman, and C. Posten
2H-NMR Study and Molecular Dynamics Simulation of the Location, Alignment, and Mobility of Pyrene in POPC Bilayers
Biophys. J., March 1, 2005; 88(3): 1818 - 1827.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
I. D. Alves, S. M. Cowell, Z. Salamon, S. Devanathan, G. Tollin, and V. J. Hruby
Different Structural States of the Proteolipid Membrane Are Produced by Ligand Binding to the Human {delta}-Opioid Receptor as Shown by Plasmon-Waveguide Resonance Spectroscopy
Mol. Pharmacol., May 1, 2004; 65(5): 1248 - 1257.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. D. Miranker
Unzipping the mysteries of amyloid fiber formation
PNAS, March 30, 2004; 101(13): 4335 - 4336.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, L.
Right arrow Articles by Zagorski, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, L.
Right arrow Articles by Zagorski, M. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Biophysical Society.